Should You Buy Assembly Biosciences, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Assembly Biosciences, Inc. (ASMB) carries a solid Quality of Company rating of 6.3/10. Trading at $26.11, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 0 of 2 CirclFi valuation models project upside for Assembly Biosciences, Inc. (ASMB) at $26.11 — the model consensus leans bearish, with a Quality Score of 6.3/10 and Value-Trap risk of 36/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Assembly Biosciences, Inc. (ASMB) in 2026?
What Is the Bull Case vs the Bear Case for Assembly Biosciences, Inc. (ASMB)?
| Bull case | Bear case — $1.68 target (-93.6%) |
|---|---|
| No active model projects meaningful upside for ASMB at $26.11. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $1.68 (-93.6%), suggesting that the market price embeds overly optimistic growth assumptions. |
| Industry headwind: manufacturing scale-up challenges represents a meaningful risk for Assembly Biosciences, Inc. and its Biotechnology peers. |
How Does ASMB Compare to Its Biotechnology Peers?
Valuation data pages: TCRX · QURE · STRO · CTMX · HRTX · ORMP · IMTX · BRNS · ADTX · EXEL · INCY
Which Other Stocks Score Like ASMB on Quality?
Closest companies to ASMB’s Quality of Company score of 6.3/10, across all industries.
Which Biotechnology Screens Does ASMB Appear In?
So Is Assembly Biosciences, Inc. (ASMB) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Assembly Biosciences, Inc. at $26.11. 2/2 models flag overvaluation, median fair value sits at $4.69 (-82.0%), and the risk-reward profile appears unfavorable. Quality at 6.3/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Assembly Biosciences, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About ASMB Stock?
Should I buy ASMB stock right now?
Based on CirclFi's multi-model analysis, 0 of 2 models see upside for ASMB at $26.11. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Assembly Biosciences, Inc.?
Key risks include: limited model coverage (2/13 active), reducing analytical confidence; wide model disagreement (358% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does ASMB compare to its competitors?
Among Biotechnology peers, ASMB holds a Quality Score of 6.3/10. Comparable companies include TCRX (QOC 6.3), QURE (QOC 6.3), STRO (QOC 6.4). The relative ranking helps investors identify whether ASMB offers better fundamental quality than alternatives in the same sector.
Is ASMB a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ASMB's Quality Score of 6.3/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy ASMB at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $1.68 to $7.71. At $26.11, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ASMB.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad